- All sections
- C - Chemistrymetallurgy
- C07K - Peptides
- C07K 14/535 - Granulocyte CSFGranulocyte-macrophage CSF
Patent holdings for IPC class C07K 14/535
Total number of patents in this class: 682
10-year publication summary
|
49
|
64
|
50
|
54
|
59
|
45
|
69
|
41
|
36
|
25
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Modernatx, Inc. | 1283 |
60 |
| Regeneron Pharmaceuticals, Inc. | 4800 |
18 |
| Institute for Research in Biomedicine (IRB) | 42 |
17 |
| Yale University | 2565 |
17 |
| Amgen Inc. | 4445 |
14 |
| Partner Therapeutics, Inc. | 29 |
13 |
| Children's Healthcare of Atlanta, Inc. | 267 |
12 |
| Emory University | 1724 |
12 |
| Replimune Limited | 41 |
12 |
| Elanco US Inc. | 717 |
11 |
| Ubiprotein, Corp. | 12 |
8 |
| The Jackson Laboratory | 376 |
7 |
| Xencor, Inc. | 410 |
7 |
| Ambrx, Inc. | 166 |
6 |
| Gradalis, Inc. | 55 |
6 |
| Hanmi Pharm. Co., Ltd. | 602 |
6 |
| Ningbo Innovative Mechanism Bioscience LLC | 7 |
6 |
| Ohio State Innovation Foundation | 2398 |
5 |
| The Regents of the University of Colorado, a body corporate | 2841 |
5 |
| The United States of America, as represented by the Secretary, Department of Health and Human Services | 3016 |
5 |
| Other owners | 435 |